Hypothesis: Microglial IKKβ/NF-κB couples to hypothalamic GnRH suppression to create a self‑reinforcing inflammaging loop

Core proposition

Chronic activation of the IKKβ/NF-κB pathway in mediobasal hypothalamic microglia drives GnRH neuronal inhibition and releases pro‑inflammatory mediators that further stimulate microglial IKKβ/NF-κB, establishing a feed‑forward circuit. This circuit amplifies systemic NF‑κB signaling, accelerates the decline of neuroendocrine output, and precipitates the canonical hallmarks of aging.

Mechanistic steps

1. Microglial IKKβ/NF-κB activation – triggered by age‑associated DAMPs or endocannabinoid dysregulation, leads to upregulation of c‑Fos, c‑Jun, PKCα/δ in adjacent GnRH neurons (see 1).
2. GnRH suppression – reduces LH/FSH secretion, lowering gonadal steroid feedback that normally restrains microglial activation.
3. Microglial‑derived signal amplification – activated microglia secrete IL‑1β, TNF‑α, and packaged exosomal miRNAs (e.g., miR‑146a) that enter the cerebrospinal fluid and peripheral circulation, potentiating NF‑κB in astrocytes, endothelial cells, and peripheral immune cells (2).
4. Peripheral inflammaging – elevated cytokines induce senescence in mesenchymal stem cells, mitochondrial dysfunction, and proteostatic stress, reproducing hallmarks such as genomic instability and loss of proteostasis.
5. Feedback to hypothalamus – circulating cytokines cross the median eminence or act via vagal afferents to reignite hypothalamic IKKβ/NF-κB, completing the loop.

Testable predictions

• Prediction 1: Selective IKKβ deletion in hypothalamic microglia (using Cx3cr1‑CreER;Ikkβ^fl/fl mice) will preserve GnRH neuron activity, attenuate systemic IL‑6/TNF‑α rise, and delay onset of senescence markers in bone marrow and muscle compared with wild‑type littermates.
• Prediction 2: Chronic intracerebroventricular administration of a GnRH agonist will improve neurogenesis and muscle mass in aged mice only when microglial IKKβ remains intact; if microglial IKKβ is simultaneously inhibited, the benefit will be additive, indicating parallel contributions.
• Prediction 3: CSF from aged mice with microglial IKKβ inhibition will show reduced levels of exosomal miR‑146a and lower NF‑κB reporter activity in cultured peripheral fibroblasts, linking the microglial secretome to peripheral hallmarks.

Falsifiability

If microglial IKKβ ablation fails to alter GnRH expression, systemic cytokine levels, or age‑related phenotype progression, the proposed feed‑forward loop is not required. Likewise, if GnRH restoration fully reverses peripheral senescence despite ongoing microglial IKKβ activity, the hypothesis that microglial signaling drives downstream hallmarks would be refuted.

Broader implication

This model situates the hypothalamus not merely as a neuroendocrine pacemaker but as an immune‑neuroendocrine hub where microglial innate signaling dictates the tempo of organismal aging. Targeting the IKKβ/NF-κB node in microglia could therefore unify interventions that currently address isolated hallmarks into a single upstream strategy.